Actively Recruiting
Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients.
Led by University Hospital, Lille · Updated on 2025-12-23
396
Participants Needed
4
Research Sites
363 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Lille
Lead Sponsor
M
Ministry of Health, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
In patients with type 2 diabetes, Roux-en-Y gastric bypass (RYGB), which excludes a portion of the stomach and the proximal intestine from the alimentary circuit, improves glucose metabolism more rapidly and more extensively than is expected from weight loss. The mechanisms of this unique effect of gastrointestinal exclusion appear to be complex and have not yet been clarified. A recent study unveil that intestinal uptake of ingested glucose is diminished by RYGB and restricted to the common limb, where food meets bile and other digestive fluids, resulting in an overall decrease of post prandial blood glucose excursion. the hypothesize that reducing the length of the common limb, which is rarely measured and highly variable in clinical practice, may significantly affect the metabolic outcome of gastrointestinal surgical procedures. The aim of the present study is to compare the impact of two variants of Roux-en-Y gastric bypass with a short common limb, the long alimentary limb or the long biliary limb Roux-en-Y gastric bypass, on type 2 diabetes remission in severely obese patients.
CONDITIONS
Official Title
Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- BMI 235 kg/m2
- All patient with type 2 diabetes
- Patients who were candidates for obesity surgery in accordance with French recommendation
You will not qualify if you...
- Severe cognitive or mental disorders
- patient who have already undergone obesity surgery
- Severe and non-stabilised eating disorders
- The likely inability of the patient to participate in lifelong medical follow-up
- Alcohol or psychoactive substances dependence
- The absence of identified prior medical management of obesity
- Diseases that are life-threatening in the short and medium term;
- Contraindications to general anaesthesia.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Chu Amiens Picardie
Amiens, France
Actively Recruiting
2
Ch Boulogne-Sur-Me
Boulogne-sur-Mer, France, 62321
Actively Recruiting
3
Hop Claude Huriez Chu Lille
Lille, France, 59037
Actively Recruiting
4
Ch de Valenciennes
Valenciennes, France
Actively Recruiting
Research Team
G
Grégory BAUD, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here